vs
安捷伦科技（A）与Astrana Health, Inc.（ASTH）财务数据对比。点击上方公司名可切换其他公司
安捷伦科技的季度营收约是Astrana Health, Inc.的1.9倍（$1.8B vs $950.5M），安捷伦科技净利率更高（17.0% vs 0.7%，领先16.3%），Astrana Health, Inc.同比增速更快（42.9% vs 7.0%），安捷伦科技自由现金流更多（$175.0M vs $-6.0M），过去两年Astrana Health, Inc.的营收复合增速更高（53.3% vs 6.9%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
Astrana Health是一家总部位于美国的价值导向型医疗服务提供商，主要服务全美符合联邦医保资格的老年群体，提供上门初级护理、慢性病管理及护理协调服务，致力于提升患者健康水平、降低不必要的医疗支出。
A vs ASTH — 直观对比
营收规模更大
A
是对方的1.9倍
$950.5M
营收增速更快
ASTH
高出35.9%
7.0%
净利率更高
A
高出16.3%
0.7%
自由现金流更多
A
多$180.9M
$-6.0M
两年增速更快
ASTH
近两年复合增速
6.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $950.5M |
| 净利润 | $305.0M | $6.6M |
| 毛利率 | 52.6% | — |
| 营业利润率 | 19.6% | 1.9% |
| 净利率 | 17.0% | 0.7% |
| 营收同比 | 7.0% | 42.9% |
| 净利润同比 | -4.1% | 184.4% |
| 每股收益（稀释后） | $1.07 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AASTH
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $950.5M | ||
| Q3 25 | $1.7B | $956.0M | ||
| Q2 25 | $1.7B | $654.8M | ||
| Q1 25 | $1.7B | $620.4M | ||
| Q4 24 | $1.7B | $665.2M | ||
| Q3 24 | $1.6B | $478.7M | ||
| Q2 24 | $1.6B | $486.3M |
净利润AASTH
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $6.6M | ||
| Q3 25 | $336.0M | $373.0K | ||
| Q2 25 | $215.0M | $9.4M | ||
| Q1 25 | $318.0M | $6.7M | ||
| Q4 24 | $351.0M | $-7.8M | ||
| Q3 24 | $282.0M | $16.1M | ||
| Q2 24 | $308.0M | $19.2M |
毛利率AASTH
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
营业利润率AASTH
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 1.9% | ||
| Q3 25 | 20.7% | 2.0% | ||
| Q2 25 | 18.0% | 3.1% | ||
| Q1 25 | 22.4% | 3.3% | ||
| Q4 24 | 24.0% | 0.1% | ||
| Q3 24 | 21.1% | 5.9% | ||
| Q2 24 | 23.1% | 6.2% |
净利率AASTH
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | 0.7% | ||
| Q3 25 | 19.3% | 0.0% | ||
| Q2 25 | 12.9% | 1.4% | ||
| Q1 25 | 18.9% | 1.1% | ||
| Q4 24 | 20.6% | -1.2% | ||
| Q3 24 | 17.9% | 3.4% | ||
| Q2 24 | 19.6% | 3.9% |
每股收益（稀释后）AASTH
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $0.12 | ||
| Q3 25 | $1.18 | $0.01 | ||
| Q2 25 | $0.75 | $0.19 | ||
| Q1 25 | $1.11 | $0.14 | ||
| Q4 24 | $1.23 | $-0.14 | ||
| Q3 24 | $0.97 | $0.33 | ||
| Q2 24 | $1.05 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $429.5M |
| 总债务越低越好 | $3.0B | — |
| 股东权益账面价值 | $6.9B | $779.3M |
| 总资产 | $12.8B | $2.2B |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
现金及短期投资AASTH
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $429.5M | ||
| Q3 25 | $1.5B | $463.4M | ||
| Q2 25 | $1.5B | $342.1M | ||
| Q1 25 | $1.5B | $260.9M | ||
| Q4 24 | $1.3B | $290.8M | ||
| Q3 24 | $1.8B | $350.3M | ||
| Q2 24 | $1.7B | $327.7M |
总债务AASTH
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.3B | — | ||
| Q1 25 | $3.3B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — |
股东权益AASTH
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $779.3M | ||
| Q3 25 | $6.4B | $775.5M | ||
| Q2 25 | $6.1B | $765.5M | ||
| Q1 25 | $6.0B | $745.4M | ||
| Q4 24 | $5.9B | $712.7M | ||
| Q3 24 | $5.9B | $704.6M | ||
| Q2 24 | $6.2B | $678.9M |
总资产AASTH
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $2.2B | ||
| Q3 25 | $12.2B | $2.2B | ||
| Q2 25 | $12.2B | $1.4B | ||
| Q1 25 | $11.9B | $1.3B | ||
| Q4 24 | $11.8B | $1.4B | ||
| Q3 24 | $11.0B | $1.3B | ||
| Q2 24 | $10.9B | $1.3B |
负债/权益比AASTH
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.53× | — | ||
| Q2 25 | 0.55× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.57× | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.34× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | $-2.9M |
| 自由现金流经营现金流 - 资本支出 | $175.0M | $-6.0M |
| 自由现金流率自由现金流/营收 | 9.7% | -0.6% |
| 资本支出强度资本支出/营收 | 5.2% | 0.3% |
| 现金转化率经营现金流/净利润 | 0.88× | -0.44× |
| 过去12个月自由现金流最近4个季度 | $993.0M | $104.5M |
8季度趋势，按日历期对齐
经营现金流AASTH
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $-2.9M | ||
| Q3 25 | $362.0M | $10.0M | ||
| Q2 25 | $221.0M | $90.9M | ||
| Q1 25 | $431.0M | $16.6M | ||
| Q4 24 | $481.0M | $-10.9M | ||
| Q3 24 | $452.0M | $34.0M | ||
| Q2 24 | $333.0M | $23.2M |
自由现金流AASTH
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $-6.0M | ||
| Q3 25 | $259.0M | $7.4M | ||
| Q2 25 | $107.0M | $89.5M | ||
| Q1 25 | $334.0M | $13.6M | ||
| Q4 24 | $388.0M | $-13.5M | ||
| Q3 24 | $360.0M | $31.7M | ||
| Q2 24 | $230.0M | $20.4M |
自由现金流率AASTH
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | -0.6% | ||
| Q3 25 | 14.9% | 0.8% | ||
| Q2 25 | 6.4% | 13.7% | ||
| Q1 25 | 19.9% | 2.2% | ||
| Q4 24 | 22.8% | -2.0% | ||
| Q3 24 | 22.8% | 6.6% | ||
| Q2 24 | 14.6% | 4.2% |
资本支出强度AASTH
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 0.3% | ||
| Q3 25 | 5.9% | 0.3% | ||
| Q2 25 | 6.8% | 0.2% | ||
| Q1 25 | 5.8% | 0.5% | ||
| Q4 24 | 5.5% | 0.4% | ||
| Q3 24 | 5.8% | 0.5% | ||
| Q2 24 | 6.5% | 0.6% |
现金转化率AASTH
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | -0.44× | ||
| Q3 25 | 1.08× | 26.69× | ||
| Q2 25 | 1.03× | 9.65× | ||
| Q1 25 | 1.36× | 2.48× | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | 2.11× | ||
| Q2 24 | 1.08× | 1.21× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
